Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma gross margin
Gross margin is gross profit as a percentage of revenue.
Xeris Biopharma's gross margin for the twelve months ending Jun 30, 2026 was 86.6%. For fiscal 2025 it was 85.4%, against 81.9% the year before. The highest annual figure on record is 85.4% in fiscal 2025.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 85.4% | +3.6 |
| FY2024 | Dec 31, 2024 | 81.9% | −0.7 |
| FY2023 | Dec 31, 2023 | 82.5% | +3.1 |
| FY2022 | Dec 31, 2022 | 79.5% | +6.3 |
| FY2021 | Dec 31, 2021 | 73.1% | +18.8 |
| FY2020 | Dec 31, 2020 | 54.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 86.4% | +3.0 |
| Q1 FY2026 | Mar 31, 2026 | 87.3% | +1.8 |
| Q4 FY2025 | Dec 31, 2025 | 87.2% | +3.0 |
| Q3 FY2025 | Sep 30, 2025 | 85.2% | +10.3 |
| Q2 FY2025 | Jun 30, 2025 | 83.4% | −0.4 |
| Q1 FY2025 | Mar 31, 2025 | 85.5% | +0.2 |
| Q4 FY2024 | Dec 31, 2024 | 84.2% | +1.3 |
| Q3 FY2024 | Sep 30, 2024 | 75.0% | −8.1 |
| Q2 FY2024 | Jun 30, 2024 | 83.8% | +3.7 |
| Q1 FY2024 | Mar 31, 2024 | 85.3% | +1.3 |
| Q4 FY2023 | Dec 31, 2023 | 82.9% | +1.9 |
| Q3 FY2023 | Sep 30, 2023 | 83.0% | +0.7 |
| Q2 FY2023 | Jun 30, 2023 | 80.1% | −0.9 |
| Q1 FY2023 | Mar 31, 2023 | 84.0% | +12.4 |
| Q4 FY2022 | Dec 31, 2022 | 81.0% | +3.8 |
| Q3 FY2022 | Sep 30, 2022 | 82.3% | +11.4 |
| Q2 FY2022 | Jun 30, 2022 | 81.0% | +19.0 |
| Q1 FY2022 | Mar 31, 2022 | 71.6% | −6.1 |
| Q4 FY2021 | Dec 31, 2021 | 77.2% | +23.4 |
| Q3 FY2021 | Sep 30, 2021 | 70.9% | +0.5 |
| Q2 FY2021 | Jun 30, 2021 | 62.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 77.7% | – |
| Q4 FY2020 | Dec 31, 2020 | 53.8% | – |
| Q3 FY2020 | Sep 30, 2020 | 70.4% | – |
See a number that looks wrong?